FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2571460968> ?p ?o ?g. }

• W2571460968 abstract "Abstract Abstract 1372 Poster Board I-394 Background: Erythropoiesis-stimulating agents (ESA) are widely used in the treatment of chemotherapy-induced anemia (CIA). ESA prescription has come under pressure in this indication due to safety concerns and because of their high acquisition price. Recent studies suggest that the efficiency of ESA can be maximized by optimising iron stores and iron bioavailability. However, little is known about the economic implications of adding intravenous ferric carboxymaltose (iv FCM; an innovative iv iron formulation allowing the administration of high iron dosages in a short time) to ESA treatment. Aims: This study aimed at estimating the incremental cost-effectiveness of adding iv FCM to ESA treatment in patients with CIA, in the Swiss health care setting. Methods: Using a Swiss third party perspective, incremental cost effectiveness of iv FCM use was expressed as cost per additional CIA patient responding to anemia treatment. Response rates and medical resource use parameters were retrieved as weighted averages from 4 randomised controlled clinical trials of solid tumour patients, which used other iv iron preparations. An assumption of equal clinical effectiveness was made. Mean treatment duration was 11.9 weeks. Unit costs were based on average ex-factory prices for ESAs. The European target ex-factory price for 100 mg iv FCM was €25. Results: Per-patient costs were determined to be €4'943 for ESA treatment alone and €5'227 for ESA plus iv FCM. The addition of iv iron to ESA increased the response rate from 55% to 74%. Hence, the incremental cost-effectiveness (cost per additional patient responding to treatment) for iv FCM was estimated at €1′455. Summary/conclusions: The addition of iv FCM to ESA treatment appears to be economically viable in patients with CIA, on the basis of a marked increase in response rate due to iv iron use. Additional economic analyses are certainly warranted, as soon as appropriate clinical data become available. Cost savings associated with reduced administration time are not covered by this analysis. Disclosures: Schwenkglenks: Amgen: Honoraria, Research Funding." @default.
• W2571460968 created "2017-01-13" @default.
• W2571460968 creator A5005829858 @default.
• W2571460968 creator A5072254367 @default.
• W2571460968 creator A5082010319 @default.
• W2571460968 date "2009-11-20" @default.
• W2571460968 modified "2023-09-27" @default.
• W2571460968 title "Cost-Effectiveness of Ferric Carboxymaltose Supplementation in Chemotherapy-Induced Anemia Patients Treated with Erythropoiesis-Stimulating Agents." @default.
• W2571460968 doi "https://doi.org/10.1182/blood.v114.22.1372.1372" @default.
• W2571460968 hasPublicationYear "2009" @default.
• W2571460968 type Work @default.
• W2571460968 sameAs 2571460968 @default.
• W2571460968 citedByCount "0" @default.
• W2571460968 crossrefType "journal-article" @default.
• W2571460968 hasAuthorship W2571460968A5005829858 @default.
• W2571460968 hasAuthorship W2571460968A5072254367 @default.
• W2571460968 hasAuthorship W2571460968A5082010319 @default.
• W2571460968 hasConcept C112930515 @default.
• W2571460968 hasConcept C126322002 @default.
• W2571460968 hasConcept C162156334 @default.
• W2571460968 hasConcept C2426938 @default.
• W2571460968 hasConcept C2777417653 @default.
• W2571460968 hasConcept C2778248108 @default.
• W2571460968 hasConcept C2778534260 @default.
• W2571460968 hasConcept C3019080777 @default.
• W2571460968 hasConcept C71924100 @default.
• W2571460968 hasConcept C98274493 @default.
• W2571460968 hasConceptScore W2571460968C112930515 @default.
• W2571460968 hasConceptScore W2571460968C126322002 @default.
• W2571460968 hasConceptScore W2571460968C162156334 @default.
• W2571460968 hasConceptScore W2571460968C2426938 @default.
• W2571460968 hasConceptScore W2571460968C2777417653 @default.
• W2571460968 hasConceptScore W2571460968C2778248108 @default.
• W2571460968 hasConceptScore W2571460968C2778534260 @default.
• W2571460968 hasConceptScore W2571460968C3019080777 @default.
• W2571460968 hasConceptScore W2571460968C71924100 @default.
• W2571460968 hasConceptScore W2571460968C98274493 @default.
• W2571460968 hasLocation W25714609681 @default.
• W2571460968 hasOpenAccess W2571460968 @default.
• W2571460968 hasPrimaryLocation W25714609681 @default.
• W2571460968 hasRelatedWork W1986875759 @default.
• W2571460968 hasRelatedWork W2010629158 @default.
• W2571460968 hasRelatedWork W2018273390 @default.
• W2571460968 hasRelatedWork W2020862550 @default.
• W2571460968 hasRelatedWork W2087734261 @default.
• W2571460968 hasRelatedWork W2104912233 @default.
• W2571460968 hasRelatedWork W2123287514 @default.
• W2571460968 hasRelatedWork W2733725362 @default.
• W2571460968 hasRelatedWork W2742286836 @default.
• W2571460968 hasRelatedWork W2754863039 @default.
• W2571460968 hasRelatedWork W2900492801 @default.
• W2571460968 hasRelatedWork W2941137485 @default.
• W2571460968 hasRelatedWork W2977579633 @default.
• W2571460968 hasRelatedWork W2979546325 @default.
• W2571460968 hasRelatedWork W2980821676 @default.
• W2571460968 hasRelatedWork W3012816515 @default.
• W2571460968 hasRelatedWork W3086175997 @default.
• W2571460968 hasRelatedWork W3104151499 @default.
• W2571460968 hasRelatedWork W3172129633 @default.
• W2571460968 hasRelatedWork W2048557602 @default.
• W2571460968 isParatext "false" @default.
• W2571460968 isRetracted "false" @default.
• W2571460968 magId "2571460968" @default.
• W2571460968 workType "article" @default.